Tingxi Guo

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

A synthetic NKG2A engager enables long-term persistence of HLA-deficient allogeneic engineered Tregs.

A synthetic NKG2A engager enables long-term persistence of HLA-deficient allogeneic engineered Tregs.

Journal: EMBO molecular medicine

Published: March 03, 2026

GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.

GNTI-122: an autologous antigen-specific engineered Treg cell therapy for type 1 diabetes.

Journal: JCI insight

Published: May 01, 2023

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy.

Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy.

Journal: Cell reports. Medicine

Published: March 08, 2023

Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation.

Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation.

Journal: ACS synthetic biology

Published: March 22, 2022

Synthetic biology: at the crossroads of genetic engineering and human therapeutics-a Keystone Symposia report.

Synthetic biology: at the crossroads of genetic engineering and human therapeutics-a Keystone Symposia report.

Journal: Annals of the New York Academy of Sciences

Published: October 05, 2021

Engineering living therapeutics with synthetic biology.

Engineering living therapeutics with synthetic biology.

Journal: Nature reviews. Drug discovery

Published: July 28, 2021

Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.

Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.

Journal: eLife

Published: November 01, 2019

Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.

Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells.

Journal: Nature biotechnology

Published: July 30, 2019

Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87.

Chaperones of the class I peptide-loading complex facilitate the constitutive presentation of endogenous antigens on HLA-DP84GGPM87.

Journal: Journal of autoimmunity

Published: November 21, 2018

Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.

Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.

Journal: Cancer immunology research

Published: July 27, 2018

Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells.

Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells.

Journal: Journal of autoimmunity

Published: May 25, 2018

DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.

DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.

Journal: Nature communications

Published: June 30, 2017

Showing 1-12 of 27

Last Updated: 09/26/2026